GLP1R and metabolic dysfunction-associated steatotic liver disease: The evidence supporting pharmacotherapy is inadequate, as the majority of clinical trials using drugs such as GLP-1 agonists and SGLT2 inhibitors have primarily included obese individuals, resulting in the efficacy and safety of these treatments for lean NAFLD remaining largely unverified (16).